The Malaysian business of Biocon subsidiary Biocon Biologics has agreed a deal to supply its recombinant human insulin brand Insugen to the country’s healthcare 26 April 2022
Privately-held German drugmaker Boehringer Ingelheim is always the last pharma major to present its annual financial results, and this year’s results have been 6 April 2022
A new broader label for heart med Jardiance (empagliflozin) will help developers Eli Lilly and Boehringer Ingelheim extend the increasingly lucrative franchise. 25 February 2022
US drugmaker Eli Lilly has announced the launch of the Lilly Institute for Genetic Medicine with an investment of approximately $700 million to establish a faci 23 February 2022
Influential pricing watchdog ICER - the Institute for Clinical and Economic Review - has released a final report into the cost-effectiveness of Eli Lilly’s GLP- 15 February 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.